HealthcareNasdaqsmall
Institutional-grade research for retail investors
SEC EDGAR: CIK 1681682NDRA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.5M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Email me the moment this company reports earnings
AI Research Report
Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.
Upgrade to Pro
Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

NDRA Stock Analysis & AI Quality Score

Data updated 2026-07-26

AI stock analysis and institutional research for ENDRA Life Sciences Inc. (NDRA), a Healthcare sector company. NDRA is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.5m in revenue and is scored on the micro-cap board instead. Top institutional holders of NDRA by reported 13-F value include Altium Capital Management, CITADEL ADVISORS, CITIZENS FINANCIAL GROUP, based on the most recent SEC filings. NDRA trades on the Nasdaq exchange and files with the SEC under CIK 1681682. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NDRA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ENDRA Life Sciences Inc. directly from SEC EDGAR.

Fun facts about ENDRA Life Sciences Inc.

Quirks, history, and lore behind NDRA — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A micro-cap medical technology company · listed on Nasdaq · headquartered in Ann Arbor, Michigan.
  • 2
    The Numbers
    Annual revenue in the low single-digit millions — this is an early-stage company burning cash while it works to commercialize its technology.
  • 3
    The History
    Founded in the 2010s, it spun out of research focused on making ultrasound imaging dramatically more useful for soft-tissue and organ assessment.
  • 4
    The Secret
    Its core trick is a contrast agent combined with a specialized acoustic receiver that lets standard ultrasound machines "see" the liver and other organs far more clearly than before — no MRI or CT required.
  • 5
    The Lore
    The company's flagship technology is designed to help detect liver disease and fibrosis non-invasively, at a time when NAFLD and NASH are reaching epidemic proportions worldwide.
  • 6
    The Giveaway
    Its ticker is four letters starting with N, its name starts with the same, and its whole mission is giving ultrasound the power of an MRI — one liver scan at a time.
▶ Think you know your stocks? Play the Daily Ticker

Net Income

Q2 2026

$159.9K

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

FY 2025
FY22 FY23 FY24 FY25

Net Income

+38.9% YoY
$-7.0MFY 2025
FY22 $-13.2MFY23 $-10.1MFY24 $-11.5MFY25 $-7.0M

Operating Income

+46.7% YoY
$-5.8MFY 2025
FY22 $-13.2MFY23 $-10.5MFY24 $-10.8MFY25 $-5.8M

EPS (Diluted)

+84.3% YoY
$-8.93FY 2025
FY22 FY23 $-2766.85FY24 $-56.94FY25 $-8.93

Total Assets

-13.4% YoY
$3.9MFY 2025
FY22 $9.3MFY23 $6.8MFY24 $4.5MFY25 $3.9M

Total Debt

FY 2025
FY22 $394.4KFY23 $28.5KFY24 $0.00FY25

Op. Cash Flow

+30.0% YoY
$-5.2MFY 2025
FY22 $-12.8MFY23 $-9.5MFY24 $-7.4MFY25 $-5.2M

Free Cash Flow

+29.9% YoY
$-5.2MFY 2025
FY22 $-13.0MFY23 $-9.6MFY24 $-7.4MFY25 $-5.2M

Get alerted when NDRA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ENDRA Life Sciences Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put NDRA on your watchlist

Track score changes the day ENDRA Life Sciences Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is NDRA a good stock to buy?

13F Pro's AI-powered analysis of ENDRA Life Sciences Inc. (NDRA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for NDRA are available on the NDRA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. NDRA is classified as a small company.

Which hedge funds own NDRA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling NDRA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ENDRA Life Sciences Inc.'s investment landscape.